One of the most widely quoted statistics in the literature on pulmonary embolism (PE) is that the mortality ofuntreated PE is 30%. The principal support given for this figure is a study published in 1960,1 in which 5 of 19 untreated patients died.
the currently prevailing view regarding prognosis, it would be reasonable to conclude that the postoperative mortality from PE ought to be about 10%. This is clearly not the case.
Either orthopedic patients have unusual emboli with a better prognosis or they are simply better studied than other groups. It is possible that symptomatic treated with conventional intercostal chest tube drainage and 5 h (95% CI 5-48 h) in patients treated with the thoracic vent (p=0.0016). The median cost of treatment with conventional intercostal chest tube drainage was $6,160 US (95% CI $3,100-14,270 US), and $500 US (95% CI 500-2,480) when treatment was performed with the thoracic vent (p=0.0016).
In a time of limited financial resources, all possibilities of reducing costs without disadvantages for the patient are of major interest. We believe that the minimally invasive treatment of spontaneous pneumothorax with the thoracic vent is an effective and inexpensive alternative to conventional chest tube drainage.
